{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:38:05Z","timestamp":1786739885481,"version":"build-2736575974"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Anaplastic lymphoma kinase (\n                      <jats:italic toggle=\"yes\">ALK<\/jats:italic>\n                      )-rearranged nonsmall cell lung cancer (NSCLC) represents a molecular subgroup with high sensitivity to\n                      <jats:italic toggle=\"yes\">ALK<\/jats:italic>\n                      inhibitors. Tyrosine kinase inhibitor crizotinib, an anticancer drug acting as an\n                      <jats:italic toggle=\"yes\">ALK<\/jats:italic>\n                      inhibitor, has shown remarkable response in\n                      <jats:italic toggle=\"yes\">ALK<\/jats:italic>\n                      -positive NSCLC. The aim of our study is to explore the adverse events (AEs) of patients on crizotinib therapy and analyze the predictability of AEs for better survival or response on NSCLC patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      The medical records of our\n                      <jats:italic toggle=\"yes\">ALK<\/jats:italic>\n                      -positive metastatic NSCLC patients who applied between years 2013 and 2018 had been reviewed retrospectively.\n                      <jats:italic toggle=\"yes\">ALK<\/jats:italic>\n                      positivity of all patients had been detected by fluorescence in situ hybridization and no other driver mutations were present. Patient demographics, performance status, smoking history, previous treatments, metastatic sites, and AEs were recorded for further analyses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Thirty-six\n                      <jats:italic toggle=\"yes\">ALK<\/jats:italic>\n                      -positive metastatic NSCLC patients were included in the study. Median follow-up was 30.1 months. Median progression-free survival (PFS) for patients who developed hepatic, cardiac, or endocrine toxicities was similar when compared to patients who did not develop. Although there was a numeric median PFS difference between patients who did develop visual disorders (18.4 months) and did not develop visual disorders (15.5 month), this was not regarded as statistically significant. However, median PFS of the patients who developed neutropenia upon crizotinib treatment (31.9 months) was found to be more favorable than the patients with normal neutrophil counts (12.8 months) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.026).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Neutropenia under crizotinib treatment was found to be associated with improved PFS suggesting that neutropenia might be an important determinant in treatment and survival strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijc.ijc_71_20","type":"journal-article","created":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T00:16:26Z","timestamp":1632960986000},"page":"251-256","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Predictive role of neutropenia under crizotinib treatment in ALK-rearranged nonsmall cell lung cancer patients"],"prefix":"10.4103","volume":"59","author":[{"given":"P\u0131nar","family":"G\u00fcrsoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burcu","family":"\u00c7akar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz","family":"Nart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erdem","family":"G\u00f6ker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-14-20240828","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2015","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"R2-14-20240828","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"R3-14-20240828","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.lungcan.2007.03.012","article-title":"National survey of non-small cell lung cancer in the United States: Epidemiology, pathology and patterns of care","volume":"57","author":"Little","year":"2007","journal-title":"Lung Cancer"},{"key":"R4-14-20240828","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1097\/JTO.0000000000000334","article-title":"The IASLC lung cancer staging project: The new database to inform the eighth of the TNM classification of lung cancer","volume":"9","author":"Rami-Porta","year":"2014","journal-title":"J Thorac Oncol"},{"key":"R5-14-20240828","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1200\/JCO.2012.45.3753","article-title":"Genotyping and genomic profiling of non-small \u2013cell lung cancer: Implications for current and future therapies","volume":"31","author":"Li","year":"2013","journal-title":"J Clin Oncol"},{"key":"R6-14-20240828","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1158\/1078-0432.CCR-10-1591","article-title":"Targeting anaplastic lymphoma kinase in lung cancer","volume":"17","author":"Shaw","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R7-14-20240828","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.lungcan.2017.12.004","article-title":"ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer","volume":"116","author":"McLeer-Florin","year":"2018","journal-title":"Lung Cancer"},{"key":"R8-14-20240828","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","article-title":"Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK","volume":"27","author":"Shaw","year":"2009","journal-title":"J Clin Oncol"},{"key":"R9-14-20240828","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2353\/ajpath.2009.080755","article-title":"EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues","volume":"174","author":"Martelli","year":"2009","journal-title":"Am J Pathol"},{"key":"R10-14-20240828","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med"},{"key":"R11-14-20240828","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK\u2013positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N Engl J Med"},{"key":"R12-14-20240828","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1021\/jm2007613","article-title":"Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)","volume":"54","author":"Cui","year":"2011","journal-title":"J Med Chem"},{"key":"R13-14-20240828","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1097\/JTO.0b013e31822591e9","article-title":"MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations","volume":"6","author":"Tanizaki","year":"2011","journal-title":"J Thorac Oncol"},{"key":"R14-14-20240828","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N Engl J Med"},{"key":"R15-14-20240828","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(12)70344-3","article-title":"Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Updated results from a phase 1 study","volume":"13","author":"Camidge","year":"2012","journal-title":"Lancet Oncol"},{"key":"R16-14-20240828","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1002\/cncr.28089","article-title":"Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients","volume":"11","author":"Weickhardt","year":"2013","journal-title":"Cancer"},{"key":"R17-14-20240828","doi-asserted-by":"crossref","first-page":"e000219","DOI":"10.1136\/esmoopen-2017-000219","article-title":"Final results of the large-scale multinational trial PROFILE 1005: Efficacy and safety of crizotinib in previously treated patients with advanced\/metastatic ALK-positive non-small-cell lung cancer","volume":"2","author":"Blackhall","year":"2017","journal-title":"ESMO Open"},{"key":"R18-14-20240828","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40780-014-0008-x","article-title":"Correlation of plasma crizotinib trough concentration with adverse events in patients with anaplastic lymphoma kinase positive non-small-cell lung cancer","volume":"1","author":"Kurata","year":"2015","journal-title":"J Pharm Health Care Sci"},{"key":"R19-14-20240828","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"R20-14-20240828","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): A randomised, open-label, phase 3 study","volume":"389","author":"Soria","year":"2017","journal-title":"Lancet"},{"key":"R21-14-20240828","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000443662","article-title":"Successful management of crizotinib-induced neutropenia in a patient with anaplastic lymphoma kinase-positive non-small cell lung cancer: A case report","volume":"9","author":"Osugi","year":"2016","journal-title":"Case Rep Oncol"},{"key":"R22-14-20240828","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.immuni.2017.09.012","article-title":"Reactive neutrophil responses dependent on the receptor tyrosine kinase c-MET limit cancer immunotherapy","volume":"47","author":"Glodde","year":"2017","journal-title":"Immunity"},{"key":"R23-14-20240828","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1006\/bbrc.1993.1801","article-title":"Hepatocyte growth factor stimulates growth of hematopoietic progenitor cells","volume":"194","author":"Mizuno","year":"1993","journal-title":"Biochem Biophys Res Commun"},{"key":"R24-14-20240828","doi-asserted-by":"crossref","first-page":"113153","DOI":"10.18632\/oncotarget.22615","article-title":"The efficacy and safety of tivantinib in the treatment of solid tumors: A systematic review and meta-analysis","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"R25-14-20240828","doi-asserted-by":"crossref","first-page":"78","DOI":"10.2482\/haigan.54.78","article-title":"Therapeutic use of low-dose corticosteroids to treat neutropenia resulting from crizotinib administration in a patient with anaplastic lymphoma kinase gene translocation-positive lung cancer","volume":"54","author":"Toyota","year":"2014","journal-title":"Haigan (Jpn J Lung Cancer"}],"container-title":["Indian Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijc.IJC_71_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:35:21Z","timestamp":1786736121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijc.IJC_71_20"}},"subtitle":["A single-institution retrospective analysis"],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ijc.ijc_71_20","relation":{},"ISSN":["0019-509X"],"issn-type":[{"value":"0019-509X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]}}}